What we help partners decide.
Target & pathway prioritization
Rank disease-relevant targets and pathways using multi-omics, disease networks and clinical-development evidence.
Indication positioning & repurposing
Identify the most credible indication, expansion opportunity or repurposing path for a target, molecule or biologic.
Target-combination discovery
Identify and rank target pairs or groups for bispecific, multispecific and other target-based therapeutic approaches.
Multimodal Therapy discovery & design
Identify and combine complementary therapeutic components into a coherent, testable Multimodal Therapy concept.
Scientific & Investment Diligence
Independent scientific and translational assessment for investment teams and external innovation opportunities.
Decision Workflow.
01
Define Scope
Clarify the specific R&D question, project scope, and required data sources.
02
Integrate Data
Integrate multi-omics, disease networks, and clinical-development evidence layers.
03
Prioritize
PleoBotâ„¢ ranks targets, indications, and combinations with expert curation.
04
Curate
Interpret biological rationale, limitations, and competitive landscape.
05
Decide
Receive ranked outputs, validation strategies, and next-step logic.
Concrete Deliverables.
Scientifically grounded outputs designed to support high-stakes R&D decisions across the value chain.
Ranked Outputs
A prioritized shortlist of targets, indications, and combinations, complete with transparent evidence fields and biological rationale.
Scientific Reports
Comprehensive biological rationale, competitive landscape analysis, and limitations integrated into a single clinical context report.
Development Recommendations
Clear Go/No-Go criteria, a recommended validation strategy, and a logical roadmap for the next stage of asset development.
Partner Workshop
An interactive review session with Tangramed scientists to challenge assumptions and align on the final action plan.
Decision support across the R&D value chain.
From complex disease biology to actionable therapeutic decisions, we provide the scientific rationale required for high-stakes R&D investments.
Partner Decision Point
Tangramed Decision Support
Preclinical Asset
Select the most credible first indication and build the biological differentiation story.
Clinical-stage Asset
Prioritize expansion indications, treatment settings and combination strategies.
Target Portfolio
Rank targets by disease relevance, translational evidence, druggability context and strategic fit.
Bispecific / Multispecific Program
Identify target pairs with complementary biology, relevant expression and defensible clinical rationale.
Standard-of-Care Add-on
Identify potential synergistic companions that may strengthen efficacy, broaden biological coverage or improve differentiation.
Program Reassessment / Post-No-Go
Determine whether an asset should be stopped, repositioned, combined or redirected to another indication.
External Innovation / Licensing
Rapidly assess the biological, translational and strategic fit of an in-licensing or acquisition opportunity.
Complex Disease Program
Design a multimodal therapeutic concept when single-target strategies are unlikely to control disease biology.
Investment Diligence
Help investment teams assess whether a therapeutic asset, target, indication or platform is scientifically and translationally credible.
Focused Decision Project
A defined question with a ranked output and a final decision meeting.
Flexible Engagement Models.
Deep-Dive Program
A broader evidence landscape with expert curation and a detailed report.
Integrated Discovery Program
Multi-stage, partner-funded analyses with agreed deliverables and review points.
From services to selected development programs
PleoBotâ„¢ powers partner decisions. Selected concepts may advance into partner-funded ITD using PleoBotâ„¢ and PAC.
Illustrative Application Areas.
Neurodegenerative Diseases
Inflammatory Disorders
Applying rational Multimodal Therapy concepts to ALS, Alzheimer's and Parkinson's, where single-target approaches have delivered limited or non-durable benefit.
Supporting projects that target multiple inflammatory pathways simultaneously to achieve more durable clinical responses.
Oncology
Cosmetics
Addressing unmet needs with rational Multimodal Therapy concepts in cancer where single-target approaches need to be supported by combination strategies.
Engineering Multimodal Therapies for skin aging with natural compounds, food supplements, and/or drug therapeutics.
Cardiovascular & Metabolic disorders
Addressing cardiovascular and metabolic diseases through rational combination strategies that balance efficacy and safety.